key: cord-0825943-jhwbyn1h
authors: Ducrest, P. J.
title: Development and Evaluation of a new Swiss Made SARS-CoV-2 antigen-detecting rapid test
date: 2021-03-26
journal: nan
DOI: 10.1101/2021.03.25.21252280
sha: 9b928293d63b9f8fe4141ba2a15de2e5c8080c46
doc_id: 825943
cord_uid: jhwbyn1h

There is an urgent need in rapid diagnostic test (RDT) to detect antigen of SARS-CoV-2 to reduce the spread of COVID-19 outbreak. We have developed a rapid and simple point-of-care lateral flow immunoassay (LFIA) detecting nucleocapsid antigen of SARS-CoV-2 in 10 minutes. The aim of this study is to evaluate the diagnostic performance and analytical sensitivity of this RDT. RT-PCR positive nasopharyngeal swab samples (n=20) for SARS-CoV-2 and 40 negative control samples were studied. Analytical sensitivity was assessed using Gamma-irradiated SARS-CoV-2 and the limit of detection (LOD) was determined at 1.4 x 10^2 TCID50/ml. Overall, RDT diagnostic sensitivity was 90% (95% confidence interval [95%CI]: 67-98%) and specificity 98% (95% CI: 85-100%). The sensitivity was 100% (95% CI: 75-100%) when using only samples with a RT-PCR Cycle threshold lower than 30. This antigen RDT displays a high diagnostic accuracy for SARS-CoV-2 antigen detection in high COVID-19 prevalence settings. Its use could be considered in the absence of routine RT-PCR facilities such in low-income countries.

The COVID-19 pandemic is a challenge for the population, healthcare systems and manufacturer of 45 medical devices. The easy and rapid detection of infected patient is crucial to shorten the spread of the Polymerase Chain Reaction (RT-PCR) but has certain inconveniences such as the time, laboratory and Anonymized leftovers of frozen Nasopharyngeal swab specimen, discharged in medium Tris EDTA 1X, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

There are several limitations to this study. First, we present here the results of a method evaluation study 207 and not a seroprevalence study. Therefore, the PPV obtained here (based on a 33.3% proportion of cases 208 defined as laboratory confirmed SARS-CoV-2 by RT-PCR) will probably be lower in a low prevalence 209 setting. Another limitation of this validation study lies in its limited sample size leading to broad 95% 210 confidence intervals, requiring confirmation of these data at a larger scale. Finally, our present 211 conclusions only apply to this RDT, and must not be applied to any other RDTs currently available.

In conclusion, this RDT is not meant to replace a SARS-CoV-2 RT-PCR but could be a reliable option 

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.25.21252280 doi: medRxiv preprint

Rapid SARS-CoV-2 antigen detection assay 227 in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand